Target trial emulation with real-world data to determine the population-level costeffectiveness of multi-gene panel sequencing in advanced melanoma

被引：0
|
作者：
Krebs, Emanuel
Weymann, Deirdre
Ho, Cheryl
Pollard, Samantha
Regier, Dean A.
机构：
[1] BC Canc Res Inst, Vancouver, BC, Canada
[2] BC Canc Vancouver, Vancouver, BC, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21508
引用
收藏
页数：1
相关论文
共 28 条
  • [21] Multi-gene panel analysis in BRCA1/2-negative patients suspected of hereditary breast and ovarian cancer syndrome: Real-world data from a single institution
    Nakahara, Mariko
    Ushiama, Mineko
    Tanabe, Noriko
    Gotoh, Masahiro
    Sakamoto, Hiromi
    Yoshida, Teruhiko
    Hirata, Makoto
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2024,
  • [22] Comparative effectiveness of cystoscopy surveillance strategies on mortality in non-muscle invasive bladder cancer: A target trial emulation using real-world data
    McGee, Emma E.
    de Albeniz, Xabier Garcia
    Eliassen, A. Heather
    Yim, Kendrick
    Dickerman, Barbra A.
    Preston, Mark A.
    Hernan, Miguel
    CANCER RESEARCH, 2024, 84 (06)
  • [23] THE DEVELOPMENT OF A FLEXIBLE AND EASY TO TAILOR DISEASE MODEL TO ESTIMATE THE OUTCOMES OF TREATMENT SEQUENCES IN ADVANCED MELANOMA BY COMBINING TRIAL AND REAL-WORLD DATA
    de Groot, S.
    Blommestein, H. M.
    Leeneman, B.
    Uyl-De Groot, C. A.
    Haanen, J. B. A. G.
    Suijkerbuijk, K. P. M.
    Aarts, M. J. B.
    van den Berkmortel, F. W. P. J.
    Blank, C. U.
    Boers-Sonderen, M. J.
    van den Eertwegh, A. J. M.
    de Groot, J. W. B.
    Hospers, G. A. P.
    Kapiteijn, E.
    de Meza, M. M.
    Piersma, D.
    van Rijn, R. S.
    Stevense-den Boer, M. A. M.
    van der Veldt, A. A. M.
    Vreugdenhil, G.
    Wouters, M. W. J. M.
    Franken, M.
    van Baal, P. H. M.
    VALUE IN HEALTH, 2022, 25 (01) : S16 - S16
  • [24] Exact-matching algorithms using administrative health claims database equivalence factors for real-world data analysis based on the target trial emulation framework
    Nishioka, Yuichi
    Morita, Emiri
    Takeshita, Saki
    Tamamoto, Sakura
    Myojin, Tomoya
    Noda, Tatsuya
    Imamura, Tomoaki
    HEALTH SERVICES AND OUTCOMES RESEARCH METHODOLOGY, 2024, 24 (4) : 427 - 439
  • [25] Head-to-head comparison of first-line FOLFIRINOX versus gemcitabine plus nabpaclitaxel (GN) in advanced pancreatic cancer (APC): A target trial emulation using Canadian real-world data.
    Boyne, Devon J.
    Brenner, Darren
    Gupta, Alind
    Mackay, Eric
    Arora, Paul
    Wasiak, Radek
    Cheung, Winson Y.
    Hernan, Miguel
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [26] HEALTH CARE COST COMPARISON ANALYSIS OF NIVOLUMAB plus IPILIMUMAB REGIMEN AND NIVOLUMAB MONOTHERAPY VERSUS ESTABLISHED ADVANCED MELANOMA THERAPIES UTILIZING CLINICAL TRIAL AND REAL-WORLD DATA
    Potluri, R.
    Okoro, T.
    Bhandari, H.
    Sabater, J.
    Ranjan, S.
    Kotapati, S.
    VALUE IN HEALTH, 2016, 19 (03) : A144 - A144
  • [27] Contextualizing a single-arm trial of ceralasertib (cer) plus paclitaxel with real-world data (RWD) in patients (pts) with advanced melanoma previously treated with anti-PD-(L)1(PDx) therapies.
    Jiang, Miao
    Lee, Jeeyun
    Jackson, Daniel
    Smith, Simon
    Khosla, Sajan
    LoembE, Bienvenu
    Dean, Emma
    Smith, Claire
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO plus IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC)
    Lemelin, A.
    Takemura, K.
    Boyne, D. J.
    Warkentin, M. T.
    Brenner, D. R.
    Cheun, W. Y.
    Wells, J. C.
    Labaki, C.
    McGregor, B. A.
    Basappa, N. S.
    Meza, L. A.
    Pal, S. K.
    Beuselinck, B.
    Mckay, R. R.
    Szabados, B. E.
    Powles, T. B.
    Yuasa, T.
    Ludwig, L.
    Choueiri, T. K.
    Heng, D. Y. C.
    ANNALS OF ONCOLOGY, 2023, 34 : S1023 - S1024
123